Plasmalogens, Controversy, and Scientific Middle Ground: A Response to Christin Glorioso, MD, PhD
- 2 days ago
- 4 min read
First, I want to thank you for taking the time to examine this topic seriously in your Substack article recently. Your piece raises important concerns, and I agree with much of your framing. Where I differ is primarily in emphasis rather than principle.
We are aligned with the biological foundation. Plasmalogens are real, structurally important membrane phospholipids enriched in brain, heart, and immune cells. Their roles in membrane architecture, redox buffering via the vinyl ether bond, and lipid signaling are well described in the literature [1]. Depletion of plasmalogens in Alzheimer’s disease and in aging has been replicated by multiple independent groups [2,3]. That part of the story is not controversial.
The unresolved question is causality. Are reduced plasmalogens contributing to disease pathogenesis, or are they downstream markers of oxidative stress, peroxisomal dysfunction, or membrane remodeling? That distinction certainly matters when considering supplementation.
Biochemical Signal vs. Clinical Proof
Where I would gently diverge from your interpretation is in how to view large within-person biochemical shifts following precursor supplementation.
If a patient demonstrates substantial, reproducible increases in circulating plasmalogen species after targeted intervention, that represents biological pathway engagement. It does not prove clinical efficacy. It does not demonstrate disease modification. But it does confirm that the intervention is interacting with the ether lipid system in a measurable way.
In Precision Longevity Medicine, we treat this as a mechanistic signal, not outcome proof. Biomarker movement alone is insufficient. But ignoring coherent biological engagement because outcome trials are incomplete is also an overcorrection. My view of the correct posture is disciplined curiosity. (See my Note at the bottom for my conception of Precision Longevity Medicine)
The Randomized Trial Evidence
Your assessment of the Fujino randomized controlled trial is accurate. The study did not meet its primary endpoint in mild Alzheimer’s disease, though subgroup analyses suggested potential signals in specific populations [4]. This does not constitute disease-modifying evidence.
At the same time, the trial demonstrated short-term safety at low dose and measurable biochemical engagement. That places plasmalogens in the category of biologically plausible with early human signals; not disproven or unworthy of clinical consideration in the right patient.
Clarifying the “900-Fold Higher Dose” Argument
One technical issue deserves clarification.
The frequently repeated statement that Prodrome dosing is “900 times higher” than the scallop oil trial is not pharmacologically valid.
The Fujino trial used 1 mg of purified intact plasmalogen, which is a complete phospholipid molecule [4]. Prodrome Neuro uses approximately 900 mg of a precursor molecule (1-O-alkyl-2-acylglycerol). That precursor:
Is not an intact plasmalogen
Has a different molecular weight
Is not fully converted to plasmalogen after ingestion
Undergoes digestion and remodeling
Milligram-to-milligram comparisons across chemically distinct molecules without molar normalization or conversion efficiency assumptions are misleading.
That said, the broader concern is legitimate. We do not have robust dose-ranging human trials establishing optimal dosing, ceiling effects, or long-term safety for precursor strategies. Early human dose-escalation work demonstrates biochemical engagement but does not establish clinical efficacy [5]. Long-term outcome data remain absent.
ALS Claims and Ethical Boundaries
On ALS, I share your discomfort.
There is no published preclinical data in established ALS animal models demonstrating efficacy of plasmalogen therapy. Claims of universal success in a terminal disease demand rigorous validation. Charging substantial sums for unproven treatment in that context raises serious ethical concerns. Regulatory scrutiny is appropriate.
These issues should be evaluated independently from the broader scientific question of plasmalogen biology in aging and neurodegeneration. Scientific plausibility in one domain does not justify extraordinary clinical claims in another.
Cholesterol Messaging and Brain Health
We also agree on cardiovascular risk.
Vascular disease is a major driver of cognitive decline and dementia risk [6]. While the cholesterol paradox in older populations is real and nuanced, suggesting that markedly elevated cholesterol is broadly safe recklessly extrapolates from the evidence. LDL reduction in appropriate risk groups remains supported by large-scale randomized trials and Mendelian randomization data [7].
Plasmalogens are not substitutes for vascular risk management. Optimal brain health requires optimal vascular health.
A Reasonable Middle Position
Here is where I land.
Plasmalogen deficiency in neurodegeneration is well documented.
Causality remains unproven.
Supplementation shows preliminary biochemical signal and limited clinical signal.
High-dose precursor strategies lack long-term outcome data.
ALS claims are unsupported.
Cardiovascular optimization remains foundational.
If plasmalogen precursors are used clinically, they should be used cautiously, adjunctively, and transparently as experimental metabolic support. They should not be marketed as disease reversal. They should not replace established therapies. They should be monitored against objective anchors including cognition, vascular markers, sleep, and inflammatory metrics. If only a lab value changes without meaningful clinical signal, the intervention should be reconsidered.
I mostly reserve plasmalogen precursor supplementation for ApoE4 patients with deficient peripheral plasmalogens and symptoms, despite doing foundational lifestyle, diet, sleep, exercise, and hormone optimization. I have seen major improvements in plasmalogen levels and improvement in clinical symptoms. In this population, I believe the potential benefits currently outweigh the risks. I continue to monitor them and look forward to seeing if other more established markers improve.
Biological plausibility plus preliminary signal deserves disciplined investigation—not dismissal. At the same time, overstatement and conflation undermine trust and harm patients. Both caution and curiosity can coexist. I suspect that we agree more than we disagree.
Note: What I Mean by “Precision Longevity Medicine”
Precision Longevity Medicine refers to a proactive, systems-based, prevention-focused model of care that integrates:
Mechanistic biology
Quantitative biomarker tracking
Individualized risk modeling
Continuous reassessment
And intellectual humility
It does not mean bypassing randomized trials. It does not mean substituting supplements for proven therapies. It means integrating emerging biology responsibly while maintaining allegiance to evidence hierarchy and patient safety.
In that framework, plasmalogens are neither miracle cure nor pseudoscience. They occupy a space of biologically plausible, incompletely validated intervention that warrants careful study—not absolutism in either direction.
References
Braverman NE, Moser AB. Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta. 2012;1822(9):1442–1452.
Han X et al. Altered lipid profiles in Alzheimer’s disease brains. J Neurochem. 2001;77:1168–1180.
Goodenowe DB et al. Peripheral ethanolamine plasmalogen deficiency in Alzheimer’s disease. Neurobiol Aging. 2007;28:1351–1361.
Fujino T et al. Effects of plasmalogen supplementation in mild Alzheimer’s disease: randomized controlled trial. EBioMedicine. 2017;17:199–205.
Dorninger F et al. Alkylglycerol supplementation and plasmalogen metabolism in humans. Front Cell Dev Biol. 2022;10:864842.
Iadecola C et al. Vascular contributions to cognitive impairment and dementia. Stroke. 2019;50:e344–e350.
Sabatine MS et al. Evolocumab and clinical outcomes in cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
Comments